Fig. 1 · Structure

Documents & Downloads

Fosaprepitant dimeglumine

Cat. No. A11069 CAS 265121-04-8

neurokinin-1 receptor antagonist

Fosaprepitant is a selective neurokinin-1 (NK-1) receptor antagonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
NK-1 receptor

Fosaprepitant dimeglumine Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Fosaprepitant dimeglumine from 2 published references. In vitro models include SK-N-AS cells.

Fosaprepitant dimeglumine In Vitro Studies

Fosaprepitant dimeglumine was evaluated for growth inhibition in SK-N-AS cells. The concentration inducing 50% growth inhibition was 0.85 μM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Growth Inhibition in SK-N-AS Cells

Cell-based study · SK-N-AS cells [1]

SK-N-AS cells were treated with Fosaprepitant dimeglumine in vitro. The concentration inducing 50% growth inhibition was 0.85 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% Inhibitory concentration (IC50)IC50 0.85 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–80 μM
Method
treated cells in vitro
Vehicle
0.9% NaCl
Reported limits
Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: Fosaprepitant dimeglumine; Compound label in the paper: Fosaprepitant

Evidence for Fosaprepitant dimeglumine as the meglumine form reported in the paper, not the free base/neutral form supplied as A11069; no salt equivalence, dose conversion or lot validation.

RESULTS > Inhibition of TACR1 signaling inhibits cell growth and leads to increased cell death (S10, S12); MATERIALS AND METHODS > Reagents and cell culture (S72); Figure 2 legend (S126)

50% Inhibitory concentration (IC50): 50% Inhibitory concentration (IC50); comparator: untreated control cultures — RESULTS > Inhibition of TACR1 signaling inhibits cell growth and leads to increased cell death (S12); Figure 2 legend (S126)

Fosaprepitant dimeglumine In Vivo Studies

Fosaprepitant dimeglumine was administered to male Sprague-Dawley rats at 30 mg/kg via the intraperitoneal route. Percent maximum possible effect (%MPE) values in control and fosaprepitant-treated groups showed no statistically significant change during the experiment. [2]

Latency Responses in Male Sprague-Dawley Rats

Animal study · Male Sprague-Dawley rats; Each experimental group had 6 animals. [2]

Male Sprague-Dawley rats received Fosaprepitant dimeglumine at 30 mg/kg by the intraperitoneal route. Neither the control nor the treated group showed statistically significant changes in percent maximum possible effect during the experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percent maximum possible effect (%MPE)Reported result The %MPE values of control and the fosaprepitant-treated groups did not show any statistically significant change during the experiment.[2]

Conditions shared by the study groups

Route
intraperitoneal route
Treatment course
once; for a week; 40 min after saline (Group I), fosaprepitant (Group III), or morphine injection (Group II and IV); Testing for latency was done at 24 h intervals.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Fosaprepitant dimeglumine 30 mg/kgphysiological saline (twice daily subcutaneously in morning and evening; Group I)The %MPE values of control and the fosaprepitant-treated groups did not show any statistically significant change during the experiment.[2]
Fosaprepitant dimeglumine 30 mg/kg
Model: Male Sprague-Dawley rats; Each experimental group had 6 animals.
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Fosaprepitant dimeglumine; Compound label in the paper: Fosaprepitant

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods (S1, S3, S7, S9, S17, S30); Results (S33)

percent maximum possible effect (%MPE): percent maximum possible effect (%MPE); comparator: physiological saline (twice daily subcutaneously in morning and evening; Group I) — Methods (S17); Results (S33)

Fosaprepitant dimeglumine 30 mg/kg · Methods (S3, S7, S9); Results (S33)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 265121-04-8
Applications neurokinin-1 receptor antagonist
Formula C37H56F7N6O16P
Molecular Weight 1004.84
Synonyms MK 0517
SMILES
C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NC(=O)N(N3)P(=O)(O)O)C4=CC=C(C=C4)F.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 183 mg/mL (182.12 mM)
Water 123 mg/mL (122.41 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fosaprepitant dimeglumine Research References

  1. [1] Henssen AG, Odersky A, Szymansky A, et al. Targeting tachykinin receptors in neuroblastoma. Oncotarget (2017). PMID: 27888795 DOI: 10.18632/oncotarget.13440 Source material
  2. [2] Prasoon P, Gupta S, Kumar R, et al. Role of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in rats. Indian J Pharmacol (2016). PMID: 27756950 DOI: 10.4103/0253-7613.186198 Source material

Added to your cart

View Cart Checkout
Loading...